A detailed history of Federated Hermes, Inc. transactions in Merus N.V. stock. As of the latest transaction made, Federated Hermes, Inc. holds 2,006,800 shares of MRUS stock, worth $85.9 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
2,006,800
Previous 2,398,800 16.34%
Holding current value
$85.9 Million
Previous $142 Million 29.36%
% of portfolio
0.23%
Previous 0.34%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$47.19 - $58.84 $18.5 Million - $23.1 Million
-392,000 Reduced 16.34%
2,006,800 $100 Million
Q2 2024

Aug 08, 2024

BUY
$39.81 - $60.2 $5.97 Million - $9.03 Million
150,000 Added 6.67%
2,398,800 $142 Million
Q1 2024

May 14, 2024

SELL
$28.03 - $51.82 $38.9 Million - $72 Million
-1,388,509 Reduced 38.17%
2,248,800 $101 Million
Q4 2023

Jan 31, 2024

BUY
$20.06 - $28.66 $15.1 Million - $21.5 Million
751,609 Added 26.05%
3,637,309 $100 Million
Q3 2023

Nov 13, 2023

BUY
$20.13 - $27.29 $4.97 Million - $6.74 Million
247,000 Added 9.36%
2,885,700 $68 Million
Q1 2023

May 08, 2023

SELL
$14.25 - $20.5 $18.3 Million - $26.4 Million
-1,285,595 Reduced 32.76%
2,638,700 $48.6 Million
Q4 2022

Feb 13, 2023

BUY
$12.8 - $23.66 $4.18 Million - $7.73 Million
326,695 Added 9.08%
3,924,295 $60.7 Million
Q3 2022

Nov 14, 2022

BUY
$18.64 - $28.93 $89,472 - $138,864
4,800 Added 0.13%
3,597,600 $72.1 Million
Q2 2022

Aug 15, 2022

SELL
$13.98 - $29.25 $1.21 Million - $2.53 Million
-86,500 Reduced 2.35%
3,592,800 $81.3 Million
Q4 2021

Feb 14, 2022

BUY
$20.0 - $32.29 $14.9 Million - $24 Million
744,500 Added 25.37%
3,679,300 $117 Million
Q3 2021

Nov 15, 2021

SELL
$16.48 - $27.23 $737,199 - $1.22 Million
-44,733 Reduced 1.5%
2,934,800 $64.6 Million
Q2 2021

Aug 16, 2021

SELL
$20.0 - $25.48 $2.09 Million - $2.67 Million
-104,724 Reduced 3.4%
2,979,533 $62.8 Million
Q1 2021

May 13, 2021

BUY
$16.14 - $29.11 $2.38 Million - $4.29 Million
147,459 Added 5.02%
3,084,257 $64.4 Million
Q4 2020

Feb 12, 2021

BUY
$11.4 - $18.36 $4.7 Million - $7.56 Million
411,862 Added 16.31%
2,936,798 $51.5 Million
Q3 2020

Nov 12, 2020

BUY
$10.57 - $16.0 $906,271 - $1.37 Million
85,740 Added 3.52%
2,524,936 $30.3 Million
Q2 2020

Aug 13, 2020

BUY
$10.5 - $17.36 $6.59 Million - $10.9 Million
627,196 Added 34.61%
2,439,196 $39.2 Million
Q1 2020

May 13, 2020

BUY
$11.34 - $19.44 $8.33 Million - $14.3 Million
734,605 Added 68.18%
1,812,000 $21.9 Million
Q4 2019

Feb 14, 2020

BUY
$14.08 - $18.5 $12.1 Million - $15.9 Million
857,395 Added 389.73%
1,077,395 $15.2 Million
Q3 2019

Nov 14, 2019

BUY
$14.55 - $20.52 $2.28 Million - $3.21 Million
156,495 Added 246.43%
220,000 $3.92 Million
Q2 2019

Aug 14, 2019

BUY
$12.93 - $16.83 $821,119 - $1.07 Million
63,505 New
63,505 $930,000

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $1.96B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.